Existing backer Bayer will invest $35m through a private placement alongside an initial public offering in which the gene editing company is initially looking to raise $90m.
Crispr Therapeutics, a Switzerland-based gene editing technology developer backed by pharmaceutical company Vertex Pharmaceuticals and chemicals and pharmaceuticals producer Bayer, filed for a $90m initial public offering in the US on Friday.
The $90m is a placeholder amount likely to be changed when Crispr sets the terms for the IPO. Bayer Global Investments, an affiliate of Bayer, has agreed to invest $35m in Crispr as part of a concurrent private placement.
Crispr is developing therapeutics based on Crispr/Cas9 gene editing…
